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There is increasing evidence that altered central mechanisms are a major factor leading to the increased sympathetic drive and altered reflex regulation of autonomic function in HF (21, 48) . Reduced synthesis of the inhibitory neuromodulator nitric oxide (NO), due to downregulation of the neuronal isoform of nitric oxide synthase (nNOS), has been suggested as a cause of the centrally mediated sympathoexcitation in HF. Previous studies indicate that nNOS levels are decreased in HF, in particular, in neurons of the paraventricular nucleus of the hypothalamus (PVN) (26, 45) . Acute inhibition of central NOS with the nonselective inhibitor N -nitro-L-arginine methyl ester (L-NAME), given either by intracerebroventricular infusion or microinjection in the PVN, increased baseline levels of RSNA (18, 43, 44) . Also central NO inhibition has been shown to improve baroreflex sensitivity of both RSNA and HR in conscious normal rabbits (18) . The role that NO plays in modulating baseline levels or baroreflex control of CSNA in the normal state, or in determining the increased CSNA in HF, has not been investigated.
The aim of the present study was to determine the role of central NO in determining the increased CSNA and altered baroreflex control of heart rate in HF. We hypothesized that increasing the levels of NO in the brain would reduce the increased cardiac sympathetic drive and restore baroreflex control of heart rate in ovine pacing-induced HF. In addition, the response to reducing endogenous NO by central inhibition of NOS with a nonselective NOS inhibitor was examined in normal and HF sheep.
METHODS
Adult merino ewes (35-45 kg body wt) were housed in individual metabolism cages in association with other sheep. Experiments were started when sheep were accustomed to laboratory conditions and human contact. Sheep were fed a diet of oaten chaff (800 g/day), and water ad libitum. All experiments were approved by the Animal Ethics Committee of the Florey Institute of Neuroscience under the guidelines laid down by the National Health and Medical Research Council of Australia.
Surgical procedures. Prior to the studies, sheep underwent a total of three aseptic surgical procedures, each separated by at least 2 wk. Anesthesia was induced with intravenous sodium thiopental (15 mg/kg), and following intubation, it was maintained with 1.5-2.0% isoflurane/O 2. In the first surgery, all sheep were prepared with a carotid arterial loop and in the sheep; to be paced into heart failure, a pacing lead was inserted into the right ventricle under fluoroscopic guidance (34, 39) . In the second surgery, lateral ventricle guide tubes were implanted under anesthesia (24) . In a separate group of animals, microinjection guide tubes (OD, 1.5 mm) were placed bilaterally with their tips 5 mm above the PVN, as previously described (6, 32) . Briefly, animals were placed in a stereotaxic frame, contrast media (0.6 ml Omnipaque; GE Healthcare, Munich, Germany) was injected into the lateral ventricles via one of the intracerebroventricular guide cannulas. Radiographs were used to identify the location of the PVN in a two-dimensional saggital plane. With the use of a micromanipulator, the guide tubes were lowered into the brain in different caudal-to-cranial angles before they were fixed into place by dental acrylic. All guide tubes were blocked with an obturator until the time of the experiment. After at least 2 wk, intrafascicular recording electrodes were implanted in the left or right cardiothoracic nerves and also in the left or right renal sympathetic nerves (31) . In all operations, animals were treated with antibiotics (900 mg, Ilium Propen; procaine penicillin; Troy Laboratories, NSW, Australia) at the start of surgery and then for 2 days postoperatively. Postsurgical analgesia was maintained with flunixin meglumine (1 mg/kg im) (Troy Laboratories) at the start of surgery, and then 4 and 16 h postsurgery. Experiments were conducted on standing, conscious sheep, and to minimize any effect of surgical stress, experiments were not started until the fourth day after implantation of the recording electrodes.
The day before implantation of recording electrodes, arterial and venous cannulas were inserted into the carotid artery and jugular vein (20, 40) . Cannulas for measurement of arterial pressure and central venous pressure were connected to pressure transducers (TDXIII, Cobe) tied to the wool on the sheep's back. Pressures were corrected to compensate for the height of the transducers above the level of the heart.
Experimental protocols. The development of HF was assessed by measurement of ejection fraction using a short-axis M-wave echocardiography on conscious sheep lying on their right side. Following placement of ventricular pacing leads, a basal measurement was made before the start of ventricular pacing at 200 -220 beats/min. Echocardiography was then performed weekly with the pacing switched off. Sheep were considered to be in HF when ejection fraction had fallen to Ͻ40%. All experiments were conducted with the pacing switched off.
CSNA was recorded differentially between the pair of electrodes with the best signal-to-noise ratio. The signal was amplified (ϫ100,000) and filtered (bandpass 300 -1,000 Hz), displayed on an oscilloscope, and passed through an audio amplifier and loud speaker. Both SNA (5,000 Hz) and arterial blood pressure (100 Hz) were recorded on a computer using a CED micro 1401 interface and Spike 2 software (Cambridge Electronic Design, Cambridge, UK).
Four days after surgical implantation of cardiac and renal sympathetic nerve electrodes, a 15-min recording of resting CSNA, RSNA, and arterial pressure was made in conscious sheep from the normal and HF groups. Following this, baroreflex curves were generated by measuring the CSNA and HR responses to increases and decreases in arterial pressure induced by intravenous administration of incremental doses of phenylephrine and sodium nitroprusside, respectively (30, 39) . Following construction of baroreflex curves, intracerebroventricular infusions of sodium nitroprusside (SNP) (500 g/ml at 1 ml/h; Bristol-Myers Squibb, Australia; n ϭ 7 in each group) or the nonselective NOS inhibitor L-NAME (6 mg·ml Ϫ1 ·h Ϫ1 at 1 ml/h, Sigma; n ϭ 6 in each group) were started. The order of the infusions was randomized, and following a recovery period of at least 24 h, the second infusion was performed. After 150 min of infusion, the baroreflex was retested, while the drugs were still being infused. The dose of SNP for intracerebroventricular infusions was determined in preliminary experiments using increasing doses of SNP, which demonstrated that this dose significantly decreased CSNA in normal animals. The dose of L-NAME used was also determined in preliminary experiments that indicated that the dose used inhibited CSNA. The time period of 150 min was chosen as preliminary experiments indicated that there was no further decrease in CSNA over longer time periods (5 h).
The PVN microinjection experiments were conducted in additional groups of normal (n ϭ 4) and HF (n ϭ 5) animals. Four days after surgical implantation of cardiac and renal sympathetic nerve electrodes, a 15-min recording of resting SNA and arterial pressure was made in conscious sheep. Following baseline recording, the effects on all cardiovascular variables of microinjection of SNP (500 mM in 500 nl) into the PVN were recorded. Variables were measured for 25 min postmicroinjection into the PVN. The response to L-NAME (5 mM in 500 nl) into the PVN was also tested in normal animals (n ϭ 5). In addition, the responses to microinjection of artificial cerebrospinal fluid (500 nl) were also determined.
Data analysis. Data were analyzed on a beat-to-beat basis using custom-written routines in the Spike 2 program (Cambridge Electronic Design). For each heartbeat, the program determined diastolic blood pressure, systolic blood pressure, mean arterial blood pressure, heart period, and the number of discriminated spikes above threshold between the following diastolic pressures, a measure of burst size (39) . The background noise was taken as the spikes/second during the highest dose of phenylephrine, when CSNA was abolished, and this was subtracted from the data collected on that day. Burst frequency was calculated as the percentage of heart beats that included spikes above background. The accuracy of burst determination was checked by eye over the 5-min control data for each sheep. We have demonstrated previously that this method gives similar results to integration and rectification of the sympathetic signal (34) .
Baroreceptor relations were constructed from data collected during infusion of phenylephrine and nitroprusside, as described previously (39) . A four-parameter sigmoidal logistic equation was used to fit the data (SigmaPlot; SPSS, ver. 8.0). Variables from the equations of all the graphs were grouped for the normal and HF animals, and average baroreflex relations were plotted. The CSNA and RSNA baroreflex parameters are expressed as a percentage of the baseline levels to allow examination of changes in range and gain. We did not compare the gain between the groups of animals, since the differing baseline levels can influence the range.
Neuronal nitric oxide synthase immunohistochemistry in brains of normal and HF sheep. For localization of nNOS, tissue from pairs of normal and HF sheep were processed together (n ϭ 3 pairs). The animals were killed with an intravenous injection of 100 mg/kg pentobarbital sodium (Lethobarb; Arnold, Reading, UK). The head was perfused via the carotid arteries with 2 liters of isotonic 0.9% NaCl solution followed by 2 liters of 4% paraformaldehyde in 0.9% NaCl solution. Brains were then removed from the skull, and a block of tissue containing the hypothalamus was postfixed at 4°C for 3 h in 4% paraformaldehyde solution. The block of tissue was then placed in 20% sucrose for 24 h before sectioning on a cryostat. The block of tissue was marked on one side to enable identification of left and right sides of the hypothalamus. Sections (40 m thick) were cut along the entire rostrocaudal axis of the hypothalamus using a cryostat (Leica Cryocut CM1850; Leica Microsystems, Wetzlar, Germany). Freefloating sections were collected into six-well tissue culture plates containing PBS before being processed.
Sections were incubated for 60 min in a blocking solution made up of 10% (vol/vol) normal horse serum and 0.3% (vol/vol) Triton X-100 (Sigma) in 0.1 M PBS, followed by rinses in PBS (3ϫ5 min). Sections were then incubated in a monoclonal mouse anti-nNOS antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) in PBS containing 0.3% (vol/vol) Triton X-100 for 24 h at room temperature. Sections were rinsed in PBS (3ϫ5 min) before a 1-h incubation in PBS containing donkey anti-mouse IgG (1:500 dilution; Invitrogen, Carlsbad, CA), 1% (vol/vol) NHS, and 0.3% (vol/vol) Triton X-100 at room temperature. After further rinses in PBS (3 ϫ 5 min), sections were mounted onto glass microscope slides with 0.5% (wt/vol) gelatin and cover slipped before examination under the microscope. This nNOS antibody has been extensively characterized in the past. Western blot analysis of the antisera revealed a band of 155 kDa, which corresponds to the size of nNOS, as shown by the manufacturer. Furthermore, the staining pattern observed with the nNOS antisera closely matched the staining patterns observed with NADPH-diaphorase histochemistry (42) . In addition, a no-primary antibody control was performed with all the above steps, with no addition of the primary antibody. Also, brain stem sections were incubated with the primary antibody to ensure that the antibody was specific for nNOSpositive neurons in the nucleus of the solitary tract (NTS).
Positive immunofluorescent-staining cells were counted under a fluorescent microscope in view fields selected from bilateral PVN transverse sections. The numbers of cells were counted in three different view fields along the dorsoventral axis of one side of the PVN at two different levels: the rostral and caudal ends of the PVN. The number of immunofluorescent cells in these six view fields was averaged to give a single value per animal.
Statistics. Data are expressed as means Ϯ SE. The differences in baseline variables, as well as changes in baroreflex parameters after an intervention, were analyzed using a paired t-test. Given the large variability between the baseline SNA measured as spikes/s in individual animals, the SNA variables were analyzed as percentage changes from control. For the infusion protocol, the data were analyzed using two-way ANOVA (GraphPad Prism, v6, La Jolla, CA). The number of nNOS-positive neurons was compared between the normal and HF animals using an unpaired t-test. P Ͻ 0.05 was considered statistically significant.
RESULTS
Changes induced by heart failure. Left ventricular ejection fraction and fractional shortening, measured in conscious sheep by echocardiography, gradually decreased over 8 -10 wk of rapid ventricular pacing at 200 -220 beats/min. In the HF animals, at 1 or 2 days before implantation of recording electrodes, ejection fraction (36 Ϯ 1%), and fractional shortening (17 Ϯ 1%) were significantly reduced compared with the prepacing values (84 Ϯ 2% and 53 Ϯ 3%, respectively, both P Ͻ 0.001). The resting level of CSNA was significantly higher in the HF group (n ϭ 7) compared with the normal group (n ϭ 9) (Fig. 1, Table 1 ). In addition, mean arterial pressure (MAP) was significantly lower in the HF group (P Ͻ 0.05). There were no significant differences in the resting levels of HR or RSNA between the normal and HF groups. In HF animals, the baroreflex control of HR was impaired, with reductions in the maximum gain and top plateau compared with normal animals ( Table 1) .
Effects of intracerebroventricular infusion of SNP on resting levels and baroreflex control of CNSA, RSNA, and heart rate. There were no changes in mean arterial pressure or heart rate during the 150-min intracerebroventricular infusion of SNP in either group of animals ( Fig. 2 ; n ϭ 7 in each group). In both groups, SNP caused similar percentage decreases in CSNA, which were significant at 150 min, but RSNA was unchanged. In the HF animals, intracerebroventricular infusion of SNP significantly increased the gain of the baroreflex control of heart rate, such that it was no longer significantly different from that in normal animals ( Table 2 ). This was accompanied Mean arterial pressure, mmHg 89 Ϯ 3 8 0 Ϯ 2* Heart rate, beats/min 81 Ϯ 5 8 8 Ϯ 8 CSNA burst incidence, bursts/100 heart beats 38 Ϯ 4 9 0 Ϯ 3* RSNA burst incidence, bursts/100 heart beats 91 Ϯ 4 9 7 Ϯ 1 Heart rate baroreflex gain Ϫ4.33 Ϯ 0.66 Ϫ2.30 Ϯ 0.26* Heart rate baroreflex range 162 Ϯ 2 135 Ϯ 6* Data are expressed as means Ϯ SE. CSNA, cardiac sympathetic nerve activity; RSNA, renal sympathetic nerve activity; HF, heart failure. *P Ͻ 0.05; n ϭ 7 in both groups except for RSNA burst incidence where n ϭ 6 for both groups.
by a selective decrease in the upper plateau of the CSNA baroreflex curve in the HF group, but there was no significant decrease in normal animals. In contrast, there was no change in the RSNA baroreflex parameters after intracerebroventricular infusion of SNP. To rule out any possible nonspecific effects of SNP, we examined the response of CSNA to intracerebroventricular infusion of S-nitroso-N-acetylpenicillamine (SNAP), and found a similar percentage decrease in CSNA to that seen with SNP (n ϭ 2; data not shown).
Effects of intracerebroventricular infusion of L-NAME on resting levels and baroreflex control of CSNA, RSNA, and heart rate. In normal animals, intracerebroventricular infusion of L-NAME significantly decreased CSNA (P Ͻ 0.05), but did not change RSNA, MAP, or HR ( Fig. 3 ; n ϭ 6 in each group), and it decreased the ranges of the baroreflex control of heart rate, CSNA, and RSNA (Table 2 ). In contrast, in HF animals, intracerebroventricular infusion of L-NAME did not decrease CSNA, and as in the normal animals, there was no fall in RSNA (Fig. 3) . In HF animals, intracerebroventricular L-NAME decreased the range of the baroreflex control of cardiac and renal SNA, as was seen in normal animals (P Ͻ 0.05) ( Table 2) .
Effects of microinjection of SNP and L-NAME into the PVN on resting SNA and MAP. Bilateral microinjection of SNP into the PVN had no effect on the baseline levels of MAP, HR, or CSNA in either normal or HF sheep (Fig. 4) . There was also no change in baseline levels of any variable following bilateral microinjection of L-NAME into the PVN of normal animals (data not shown).
Number of nNOS-positive neurons in the PVN of normal and heart failure sheep. In both normal and HF animals, neurons in the PVN were stained for nNOS (Fig. 5) .The data are presented as the means of the values from the rostral and caudal levels of the PVN. The number of nNOS-positive neurons in the PVN was significantly lower in the sheep in HF than in the normal sheep (42 Ϯ 2 vs. 24 Ϯ 6 cells/view field, P Ͻ 0.05, respectively).
DISCUSSION
The main findings of this study are that increasing brain levels of NO with intracerebroventricular infusion of SNP in conscious sheep in HF reduced the elevated CSNA and improved the baroreflex control of HR. The intracerebroventricular infusion of SNP caused similar percentage decreases in CSNA in both normal and HF sheep, whereas microinjection of SNP into the PVN did not cause cardiac sympathoinhibition in either group. Reduction of endogenous central NO levels with intracerebroventricular infusion of L-NAME decreased CSNA in normal but not HF sheep. At this level of HF, there was no significant increase in RSNA, and the treatments did not alter RSNA in either group. These findings indicate that central levels of endogenous NO provide a tonic drive that contributes to the resting level of CSNA in normal sheep, but this effect is absent in HF. In contrast, pharmacologically increasing central levels of NO in both the normal and HF groups reduced CSNA and improved sensitivity of the HR baroreflex by actions on sites other than the PVN.
Effects of intracerebroventricular infusion of SNP in normal and HF sheep. The large increase in baseline levels of CSNA in HF sheep, with minimal changes in RSNA, confirms our previous findings (30) . In both normal sheep and sheep in HF, administration of SNP into the cerebral ventricles reduced CSNA, but had no effect on RSNA. These findings differ from those in anesthetized dogs in which intracerebroventricular SNP decreased MAP and RSNA in healthy animals, and although MAP fell in dogs with pacing-induced HF, there was ·h Ϫ1 ) in a group of normal () and HF (OE) sheep. n ϭ 7/group. *Significant effect of time on CSNA levels P Ͻ 0.05. Note that the decrease in CSNA is similar in both the normal and the HF groups. no decrease in RSNA (15) . In addition, in anesthetized WistarKyoto rats, central administration of nitric oxide decreased blood pressure (1) . The use of anesthesia in these studies may account for the contrasting findings compared with those in conscious sheep. Indeed, intracerebroventricular infusion of a NO donor in conscious rabbits caused no change in the baseline levels of blood pressure or RSNA, although the baroreflex control of RSNA was attenuated (18) .
Our result that intracerebroventricular infusion of SNP improved baroreflex gain of heart rate in HF animals suggests that reduced levels of central NOS may play a role in setting the impaired baroreflex control of HR in HF. Importantly, intracerebroventricular infusion of SNP did not alter baroreflex gain of CSNA, suggesting that its action to sensitize the baroreflex control of HR is due to improved vagal control of HR. This agrees with our previous finding that the baroreflex control of CSNA was not altered in HF. We suggested that in HF, the decreased sensitivity of the HR reflex was vagally mediated (39) , which is in accord with findings in patients with HF (3, 28) . An effect of NO on vagal activity is supported by the finding that the tachycardia in response to nNOS antisense in the PVN is vagally mediated (37) . In addition, nitric oxide has been shown to influence parasympathetic control of heart rate by actions in the dorsal motor nucleus, as well as the nucleus ambiguus (11, 35) .
Effects of microinjection of SNP into the PVN in normal and HF sheep. The present findings that microinjection of SNP into the PVN did not change baseline levels of CSNA in normal or HF sheep suggest that the PVN is not the site where increased NO levels following intracerebroventricular infusion of SNP caused inhibition of CSNA. This is in accord with our findings that the PVN does not play a role in driving the increased CSNA in ovine HF (32) . It is unlikely that the absence of a response to SNP is a dose-related issue. We tested the responses to higher doses of SNP (1.0 M, 500 nl each side) into the PVN and observed no changes in either MAP or RSNA (n ϭ 2; data not shown). The dose of SNP (0.5 M) that we used corresponded to a microinjection of about 130 g of SNP into the PVN. This dose given intravenously will decrease blood pressure, so it is unlikely that the dose of SNP used was not high enough. It is also unlikely that the absence of changes is related to an inability to target the PVN. In three of the normal animals, we also tested the responses to bicucilline and found an increase in MAP and a decrease in RSNA, as previously reported (32), indicating effective targeting of PVN neurons in these animals. Data are expressed as means Ϯ SE, CSNA, cardiac sympathetic nerve activity; RSNA, renal sympathetic nerve activity; HR, heart rate; SNP, sodium nitroprusside L-NAME, N w nitro-L-arginine methyl ester; BP50 -aterial pressure at the midpoint of the baroreflex curve range. *P Ͻ 0.05 between control period and after intracerebroventricular infusion of SNP (n ϭ 7/group) or L-NAME (n ϭ 6/group). #P Ͻ 0.05 between normal and HF groups.
Although anesthesia can influence sympathetic responses to stimulation of the PVN (12) , it is possible that other factors contribute to the different responses in this study and previous studies. One possibility is that in previous studies, the dose of SNP microinjected was excessively high, leading to nonspecific or toxic effects. In conscious rats, unilateral PVN microinjections of SNP (0.5-1.0 M, about 13-26 g) decreased MAP (17) , and in normal anesthetized rats, microinjection of SNP (100 nmol, about 20 g) decreased MAP, heart rate, and RSNA (43) . Although the inhibition of RSNA in these studies is likely a direct central effect of SNP, as the renal inhibition occurred in the presence of a fall in blood pressure, it is important to note that the intravenous dose of SNP required to produce large falls in blood pressure in rats is 5-10 g, raising the possibility that changes observed after SNP infusions or microinjections may result from supraphysiological increases in NO levels.
Decreased levels of nNOS have been found in the hypothalamus and brain stem of rats with HF (7, 26) . The functional importance of this as a cause of the increased RSNA in HF is shown by the beneficial effects of nNOS gene transfer into the PVN and rostral ventrolateral medulla (RVLM) (38, 46) . The decreased number of nNOS-positive neurons in the PVN of sheep in HF is consistent with previous findings in rats, but this does not account for the increased CSNA in HF, as indicated by the lack of effect of PVN microinjections of SNP. Currently, the functional significance of the decrease in nNOS neurons in the PVN of HF sheep remains unclear, and further studies are required to ascertain the specific nuclei responsible for the decrease in CSNA during intracerebroventricular infusion of SNP.
Changes in baseline levels during intracerebroventricular infusion of L-NAME. Central administration of L-NAME selectively inhibited CSNA in normal sheep, suggesting a sympathoexcitatory action of NO. The inhibition of CSNA was not baroreflex-mediated because treatment with L-NAME caused a small increase in MAP (3 mmHg), which the baroreflex curve indicates would reduce CSNA by ϳ21%, not by the 50 Ϯ 12% observed. It is important to note that there is substantial evidence that nitric oxide may be sympathoexcitatory in some brain regions. In anesthetized rats, SNP microinjected into the RVLM increased MAP and RSNA, suggesting an excitatory role for NO in the RVLM (10, 23) . These responses have been reproduced in conscious rats, where microinjection of SNP into the RVLM increased arterial pressure (16) . Finally, in conscious rats, intravenous infusion of L-NAME, combined with infusion of hydralazine to maintain baseline levels of blood pressure, caused profound inhibition of RSNA and bradycardia, suggesting a sympathoexcitatory role for NO (22) .
Interestingly, the inhibition of CSNA by L-NAME was absent in sheep in HF. The finding in normal animals of similar inhibition of CSNA with increases in NO during intracerebroventricular infusion of SNP and with decreases of endogenous NO with inhibition of nNOS during intracerebroventricular infusion of L-NAME probably reflects actions of these drugs at different sites in the brain. Collectively, our data concur with previous studies that there are multiple sites in the brain, where NOS exists and NO may have both excitatory, as well as inhibitory roles. While previous rodent work has established the PVN as a site where NO can inhibit RSNA, our data in conscious sheep suggest that the PVN does not modulate ) in a group of normal () and HF (OE) sheep; n ϭ 6/group, #Significant interaction between time and group P Ͻ 0.05; i.e., there is a significant decrease in CSNA in the normal but not in the HF group. 4 . Effects of bilateral microinjection of sodium nitroprusside (500 mM in 500 nl) into the PVN on mean arterial blood pressure, heart rate, cardiac, and renal SNA in conscious normal (n ϭ 5; ) and HF sheep (n ϭ 4; OE). The distribution of all injection sites is shown in the schematic drawing adapted from coronal sections from one animal. The dots show the center of injection sites as visualized by the distribution of blue dye. Dots indicate the paraventricular nucleus of the hypothalamus (PVN) sodium nitroprusside injection sites in the normal (OE) and heart failure animals (gray circles). OC, optic chiasm.
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CSNA. The nucleus of the solitary tract is a further brain area, where NOS is present, and given the ability of NTS neurons to modulate SNA (36) , this remains a putative site where NO may exert sympathoinhibitory actions. It is also interesting to note that the response to inhibition of NOS was restricted to SNA to the heart and not to the kidney, which is not surprising, considering the evidence that different central pathways control these two sympathetic outflows (32, 33) .
Our results contrast with previous studies that observed increased RSNA during central administration of L-NAME in normal animals (15, 18) . Recent studies in conscious rodents also showed an increase in MAP with microinjection of L-NAME into the PVN (17) . In our study, L-NAME given intracerebroventricularly, or into the PVN, did not significantly increase MAP, and it is unclear why this is the case. Inhibition of NOS in central neurons of normal animals using intracerebroventricular infusion of L-NAME decreased the range of the baroreflex control of CSNA, RSNA, and heart rate, but we found no change in the baroreflex gain of heart rate in the normal animals. The decreased heart rate range after L-NAME infusion probably contributes to the decreased CSNA and RSNA baroreflex range because a lower heart rate leads to fewer sympathetic bursts per unit time leading to a decreased SNA. The associated increase in burst amplitude with slower heart rates usually does not compensate for the decrease in the number of bursts. The lack of responses to microinjection of L-NAME into the PVN suggests that nitric oxide within the PVN of normal sheep does not play an important role in mediating the levels of cardiac or renal SNA.
Differential regulation of CSNA and RSNA. A recurring theme in the results obtained in our study is the differential regulation of sympathetic drive to the heart and the kidney. Previous studies have indicated a role for NO in differential regulation of SNA to the kidney and skeletal muscle in rats, rabbits, and sheep (9, 19, 29) . Our finding of differential changes in CSNA and RSNA after intracerebroventricular infusion of L-NAME highlights the role of central NO in the differential modulation of SNA to different organs. The sites of action at which NOS mediates this differential control remain unclear since NOS is present in many cardiovascular nuclei, including the NTS and RVLM. Given previous evidence that the NTS is one target for the differential regulation of SNA by NO (36) , it remains a candidate nucleus where NO may exert a differential action on CSNA and RSNA.
Perspectives and Significance
It is well established that HF is associated with sympathetic activation and impaired baroreflex control of heart rate, both of which are associated with poor outcomes. Previous studies indicate that the renal sympathoexcitation observed in HF is mediated by the downregulation of NOS and reduced inhibition by NO within the CNS (7, 26, 43, 47) . Our data confirm the downregulation of NOS-positive neurons in the PVN in HF and show that increasing central NO by intracerebroventricular infusion of SNP inhibited CSNA, although not RSNA. In contrast, inhibition of endogenous NO by intracerebroventricular infusion of L-NAME inhibited CSNA in normal but not HF sheep, indicating sympathoexcitation of CSNA by endogenous NO in the healthy state. These data suggest that NO can have both excitatory and inhibitory actions in the brain with endogenous NO having a predominantly excitatory effect on CSNA in normal animals. While the effects of nitric oxide on RSNA appear to be mediated via the PVN in rodents (25, 44) , this does not appear to be the important site modulating CSNA in conscious sheep with HF. Further studies are required to determine the sites of action of endogenous and exogenously administered NO on CSNA. 
